A narrative review of MRI acquisition for MR-guided-radiotherapy in prostate cancer

Quant Imaging Med Surg. 2022 Feb;12(2):1585-1607. doi: 10.21037/qims-21-697.

Abstract

Magnetic resonance guided radiotherapy (MRgRT), enabled by the clinical introduction of the integrated MRI and linear accelerator (MR-LINAC), is a novel technique for prostate cancer (PCa) treatment, promising to further improve clinical outcome and reduce toxicity. The role of prostate MRI has been greatly expanded from the traditional PCa diagnosis to also PCa screening, treatment and surveillance. Diagnostic prostate MRI has been relatively familiar in the community, particularly with the development of Prostate Imaging - Reporting and Data System (PI-RADS). But, on the other hand, the use of MRI in the emerging clinical practice of PCa MRgRT, which is substantially different from that in PCa diagnosis, has been so far sparsely presented in the medical literature. This review attempts to give a comprehensive overview of MRI acquisition techniques currently used in the clinical workflows of PCa MRgRT, from treatment planning to online treatment guidance, in order to promote MRI practice and research for PCa MRgRT. In particular, the major differences in the MRI acquisition of PCa MRgRT from that of diagnostic prostate MRI are demonstrated and explained. Limitations in the current MRI acquisition for PCa MRgRT are analyzed. The future developments of MRI in the PCa MRgRT are also discussed.

Keywords: Magnetic resonance-guided-radiotherapy (MRgRT); diffusion weighted imaging (DWI); integrated magnetic resonance imaging and linear accelerator (MR-LINAC); multi-parametric magnetic resonance imaging (mpMRI); prostate cancer (PCa).

Publication types

  • Review